ABSTRACT

Background

Hydroxychloroquine (HCQ) was one of the earliest drugs to be recommended for tackling the COVID-19 threat leading to its widespread usage. We provide preliminary findings of the system, established in a tertiary care academic center for the administration of HCQ prophylaxis to healthcare workers (HCW) based on Indian Council of Medical Research (ICMR) advisory.

Methods

A dedicated clinical pharmacology and internal medicine team screened for contraindications, administered informed consent, maintained compliance and monitored for adverse events.

Results

Among the 194 HCWs screened for ruling out contraindications for prophylaxis, 9 were excluded and 185 were initiated on HCQ. A total of 55 adverse events were seen in 38 (20.5%) HCWs out of which 70.9%, 29.1% were mild and moderate & none were severe. Before the completion of therapy, a total of 23 participants discontinued. Change in QTc interval on day 2 was 5 (IQR: −3.75, 11) ms and the end of week 1 was 15 ms (IQR: 2, 18). Out of the 5 HCW who turned positive for COVID-19, 2 were on HCQ.

Conclusion

HCQ prophylaxis was found to be safe and well tolerated in HCW when administered after appropriate screening and with monitoring for adverse events.

中文翻译：

---

根据国家建议管理和监测羟氯喹预防 COVID-19 的系统：印度三级护理机构的初步经验

摘要

背景

羟氯喹 (HCQ) 是最早被推荐用于应对 COVID-19 威胁的药物之一，从而导致其广泛使用。我们提供了该系统的初步调查结果，该系统是根据印度医学研究委员会 (ICMR) 的建议，在三级护理学术中心建立的，用于对医护人员 (HCW) 进行 HCQ 预防管理。

方法

专门的临床药理学和内科团队筛选禁忌症、给予知情同意、保持依从性并监测不良事件。

结果

在为排除预防禁忌症而进行的 194 名医护人员筛查中，9 名被排除，185 名开始接受 HCQ。38 名医护人员 (20.5%) 共出现 55 起不良事件，其中 70.9%、29.1% 为轻度和中度，没有严重事件。在治疗完成之前，共有 23 名参与者停止治疗。第 2 天 QTc 间期的变化为 5 (IQR: -3.75, 11) ms，第 1 周结束时为 15 ms (IQR: 2, 18)。在 5 名 COVID-19 检测结果呈阳性的医护人员中，有 2 人正在接受 HCQ。

结论

研究发现，在适当的筛查和不良事件监测后进行 HCQ 预防对于医护人员来说是安全且耐受性良好的。